Memphasys Ltd Lands First UK Felix Orders Within Weeks
Memphasys breaks into the UK with first Felix™ orders within weeks
Memphasys (ASX: MEM) has secured entry into the United Kingdom market, with four UK IVF groups now actively commercial trialling its Felix™ System and first commercial orders received within weeks of initial in-market engagement. The UK ranks among the world’s largest fertility markets, with more than 100,000 treatment and preservation cycles conducted annually.
Orders have come from a broad cross-section of customers. These range from IVF groups conducting more than 10,000 cycles per annum through to smaller independent clinics, signalling broad appeal across the market.
The speed of progression, moving from introduction to commercial trial to order in a matter of weeks, points to clinical demand in one of the most sophisticated and demanding fertility markets globally.
When big ASX news breaks, our subscribers know first
A rapid commercial progression in the UK
The Company’s ability to operate commercially in the UK is underpinned by its “UKCA (UK Conformity Assessed) Mark” approval, secured earlier in 2026, which provides “immediate and direct market access.” That regulatory clearance opened the door to a structured commercial push on the ground.
In recent weeks, A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth, conducted a programme of direct clinic visits across London and the broader UK, meeting with IVF clinics and clinical teams to introduce the Felix™ System and progress commercial discussions.
According to the Company, the results of this engagement have been swift and commercially meaningful:
-
Four UK IVF groups are now actively commercial trialling the Felix™ System
-
First orders have been received from multiple clinics
-
Commercial agreements are close to being finalised and are expected to be “materially larger, multiple year and minimum volume based commercial relationships”
-
Trialling clients range from large multi-site conglomerates conducting more than 10,000 cycles per annum to smaller private clinics
-
Commercial trials have resulted in sales of consoles and several hundred cartridges to these groups
For commercial reasons, the Company has not disclosed the identities of the clinics at this stage. No dollar value for the orders has been provided.
How Felix™ works and why the recurring-revenue model matters
The Felix™ System is a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction. By combining electrophoresis and size-exclusion membranes, the system aims to deliver a fast, gentle and standardised sperm selection process.
Felix™ is designed to replace traditional centrifugation, a spinning technique that can cause cellular stress and DNA damage to sperm. The Company positions Felix™ as a repeatable alternative for clinicians in the IVF laboratory.
The commercial appeal for investors centres on a single-use cartridge-driven recurring revenue model. Each clinic onboarded represents an ongoing and growing revenue stream as procedure volumes and cartridge utilisation increase over time. This is why console placements and cartridge volume both matter, as the consoles establish the install base while cartridges drive repeat purchasing.
The Felix commercial rollout had already generated A$111,600 in March quarter 2026 revenue across four regions, establishing a baseline from which the UK and other new geographies are now adding incremental volume.
| Feature | What it does | Why it matters to investors |
|---|---|---|
| UKCA Mark approval | Provides immediate and direct UK market access | Removes the regulatory barrier to commercial sales in a 100,000+ cycle market |
| Single-use cartridge model | Each procedure consumes a cartridge | Creates recurring, repeat-purchase revenue rather than one-off sales |
| Multi-site conglomerates | Onboards groups conducting >10,000 cycles p.a. | Offers scale and the potential for higher cartridge utilisation |
| Multi-year agreements | Commercial relationships expected to be multi-year and minimum-volume based | Supports forward revenue visibility if finalised |
ESHRE and a widening global commercial footprint
A/Prof Bakos will return to London in the coming weeks to attend ESHRE, one of the world’s premier reproductive medicine conferences, where Memphasys is a participating Exhibitor. The Company expects the event to generate further clinical engagement, advance existing pipeline opportunities and support additional order conversion across the UK and Europe.
The UK progression forms part of a broader strategy to build a global network of Felix™ adopting clinics. The Company reports that this commercial momentum spans MENA, Europe, SE Asia, India, Japan and Australia, with further customer conversions and contracts anticipated.
A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth
“The response from UK IVF Groups has been exceptional. Within a very short period of initial engagement, we have moved from introduction to Felix commercial trialling and orders across multiple sites, reflecting the strength of the clinical evidence behind Felix™ and the genuine unmet need it addresses in the IVF laboratory. The UK is a sophisticated and demanding market, and the speed at which clinicians have recognised the value of Felix™ gives us considerable confidence as we head into ESHRE. We expect this momentum to build further over the coming weeks.”
The next major ASX story will hit our subscribers first
What it means for investors
The UK update brings together several elements relevant to the investment case. Memphasys has entered a market of more than 100,000 annual fertility cycles, converted early engagement into orders within weeks, and is generating cartridge sales that feed its recurring-revenue model.
Commercial agreements expected to be multi-year and minimum-volume based are approaching finalisation, which, if completed, would add forward revenue visibility. The near-term ESHRE appearance offers a potential catalyst for further order conversion across the UK and Europe.
The Vietnam commercialisation deal, a two-year exclusive agreement worth A$530,000 with structured quarterly cartridge growth, illustrates how Memphasys is building contracted minimum-volume relationships across its international network ahead of full regulatory activation in each market.
No revenue figures or clinic identities have been disclosed, so the commercial scale of these early orders remains undisclosed. The Company anticipates momentum building “over the coming weeks,” framing the period ahead as the next catalyst window for investors to watch.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of market-moving announcements the moment they hit. Click the “Free Alerts” button at StockWire X to start receiving alerts today.